Research Analysts Offer Predictions for Cencora Q1 Earnings

Cencora, Inc. (NYSE:COR) – Analysts at Leerink Partnrs lifted their Q1 2025 earnings per share estimates for shares of Cencora in a note issued to investors on Wednesday, November 6th. Leerink Partnrs analyst M. Cherny now forecasts that the company will post earnings of $3.45 per share for the quarter, up from their previous estimate of $3.43. The consensus estimate for Cencora’s current full-year earnings is $14.86 per share. Leerink Partnrs also issued estimates for Cencora’s Q2 2025 earnings at $4.12 EPS, Q3 2025 earnings at $3.73 EPS, Q4 2025 earnings at $3.70 EPS, FY2025 earnings at $14.99 EPS, FY2027 earnings at $18.91 EPS and FY2028 earnings at $20.72 EPS.

Other research analysts have also issued reports about the stock. Bank of America reiterated a “neutral” rating and set a $245.00 price objective (down from $275.00) on shares of Cencora in a report on Wednesday, September 18th. UBS Group boosted their price objective on shares of Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research note on Thursday. Robert W. Baird increased their target price on Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a research report on Thursday. Leerink Partners lowered their price target on Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a research report on Monday, October 7th. Finally, Evercore ISI lifted their price objective on Cencora from $250.00 to $285.00 and gave the company an “outperform” rating in a research note on Thursday. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $271.20.

Cencora Stock Performance

Cencora stock opened at $248.41 on Friday. The stock has a fifty day moving average price of $231.95 and a 200 day moving average price of $230.79. Cencora has a 52 week low of $191.11 and a 52 week high of $251.00. The firm has a market capitalization of $48.95 billion, a P/E ratio of 33.08, a PEG ratio of 1.55 and a beta of 0.44. The company has a current ratio of 0.88, a quick ratio of 0.55 and a debt-to-equity ratio of 4.84.

Cencora Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, November 29th. Investors of record on Friday, November 15th will be paid a $0.55 dividend. This is a boost from Cencora’s previous quarterly dividend of $0.51. The ex-dividend date of this dividend is Friday, November 15th. This represents a $2.20 annualized dividend and a dividend yield of 0.89%. Cencora’s payout ratio is 27.16%.

Insider Activity at Cencora

In other news, Chairman Steven H. Collis sold 21,509 shares of the business’s stock in a transaction dated Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total value of $5,071,822.20. Following the completion of the sale, the chairman now owns 285,088 shares of the company’s stock, valued at approximately $67,223,750.40. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 15.80% of the stock is currently owned by company insiders.

Institutional Trading of Cencora

A number of institutional investors and hedge funds have recently modified their holdings of the business. New Millennium Group LLC bought a new stake in shares of Cencora in the 2nd quarter worth approximately $26,000. TCTC Holdings LLC acquired a new stake in shares of Cencora in the 1st quarter worth about $29,000. TFO Wealth Partners LLC bought a new stake in Cencora in the 1st quarter valued at about $30,000. MFA Wealth Advisors LLC bought a new stake in Cencora in the 2nd quarter valued at about $30,000. Finally, Concord Wealth Partners acquired a new position in Cencora during the 3rd quarter valued at about $30,000. 97.52% of the stock is owned by institutional investors and hedge funds.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.